Business Description
Helix BioPharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA4229101098
Description
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.33 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 21 | |||||
| 3-Year EPS without NRI Growth Rate | 24.6 | |||||
| 3-Year FCF Growth Rate | 30.1 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 77.18 | |||||
| 9-Day RSI | 72.3 | |||||
| 14-Day RSI | 68.43 | |||||
| 6-1 Month Momentum % | -18.18 | |||||
| 12-1 Month Momentum % | -10 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.46 | |||||
| Quick Ratio | 1.46 | |||||
| Cash Ratio | 1.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.7 | |||||
| Shareholder Yield % | -13.67 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -1446.34 | |||||
| ROA % | -237.03 | |||||
| ROIC % | -514.62 | |||||
| ROC (Joel Greenblatt) % | -15823.53 | |||||
| ROCE % | -1444.12 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 68.33 | |||||
| EV-to-EBIT | -8.79 | |||||
| EV-to-EBITDA | -8.8 | |||||
| EV-to-FCF | -7.7 | |||||
| Earnings Yield (Greenblatt) % | -11.37 | |||||
| FCF Yield % | -11.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Helix BioPharma Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -0.037 | ||
| Beta | -1.02 | ||
| Volatility % | 33.15 | ||
| 14-Day RSI | 68.43 | ||
| 14-Day ATR (C$) | 0.008876 | ||
| 20-Day SMA (C$) | 0.20175 | ||
| 12-1 Month Momentum % | -10 | ||
| 52-Week Range (C$) | 0.15 - 0.26 | ||
| Shares Outstanding (Mil) | 229.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Helix BioPharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Helix BioPharma Corp Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Helix BioPharma Corp Frequently Asked Questions
What is Helix BioPharma Corp(TSX:HBP)'s stock price today?
The current price of TSX:HBP is C$0.23. The 52 week high of TSX:HBP is C$0.26 and 52 week low is C$0.15.
When is next earnings date of Helix BioPharma Corp(TSX:HBP)?
The next earnings date of Helix BioPharma Corp(TSX:HBP) is .
Does Helix BioPharma Corp(TSX:HBP) pay dividends? If so, how much?
Helix BioPharma Corp(TSX:HBP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers